VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

20th May 2014 - New research

PRAMIPEXOLE CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE

European Journal of Neurology [2014] 21 (5) : 736-743 (R.A.Hauser, A.H.Schapira, P. Barone, Y.Mizuno, O.Rascol, M.Busse, C.Debieuvre, M.Fraessdorf, W.Poewe) Complete abstract

The long term safety and efficacy of pramipexole was assessed as an extended-release oral formulation and immediate release formulation in early or advanced Parkinson's Disease. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist. For more information go to Pramipexole

In those people with early Parkinson's Disease the reported side effects were somnolence (15%), peripheral edema (11%) and back pain (10%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 6.6 when using extended release pramipexole and 6.3 when using immediate release pramipexole. In those people with advanced Parkinson's Disease the reported side effects were dyskinesia (27%), somnolence (13%), and impulse control disorders (1%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 11.5 when using extended release pramipexole and 9.1 when using immediate release pramipexole.

In both early and advanced Parkinson's Disease better efficacy was achieved when using the extended release version of pramipexole. The adverse events were typical for dopaminergic drugs. For more news go to Parkinson's Disease News.

FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE CLICK HERE

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2014  Viartis
 
2015-08-07 22:56:13
 
[email protected]